Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIKTIMVO vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NIKTIMVO is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, lowering blood glucose levels independently of insulin.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction.,To slow the progression of diabetic kidney disease in adults with type 2 diabetes and chronic kidney disease.
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
Nivolumab 240 mg intravenously over 30 minutes every 2 weeks, or 480 mg intravenously over 30 minutes every 4 weeks.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life: 18 hours (range 14-22 hours), supporting once-daily dosing.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
NIKTIMVO is primarily metabolized via glucuronidation by UGT1A9, with minor metabolism via CYP3A4.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Renal excretion: 70% as unchanged drug; fecal elimination: 30% as metabolites.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
95% bound primarily to albumin and alpha-1-acid glycoprotein.
82–88% bound to plasma proteins (primarily albumin).
0.8 L/kg (0.6-1.0 L/kg), indicating extensive tissue distribution (e.g., liver, kidney).
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral: 85% with food; IV: 100%.
Oral: 65–80% (median 73%)
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (Cr Cl <30 m L/min) has not been studied; use with caution.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate to severe (Child-Pugh B or C): not studied; use with caution.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
For patients aged 12 years and older: same as adult dosing. For children <12 years: not recommended due to lack of data.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment required; efficacy and safety similar to younger adults; monitor for immune-related adverse events more closely.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
There is no black box warning for NIKTIMVO.
None
Ketoacidosis, including life-threatening cases, in patients with type 1 or type 2 diabetes.,Volume depletion, hypotension, and acute kidney injury, especially in patients with impaired renal function or on diuretics.,Urosepsis and pyelonephritis.,Hypoglycemia when used with insulin or insulin secretagogues.,Necrotizing fasciitis of the perineum (Fournier gangrene).
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.,History of serious hypersensitivity reaction to NIKTIMVO.,Concomitant use with other SGLT2 inhibitors.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
No specific food interactions have been established. However, patients should maintain a balanced diet and avoid grapefruit and other known CYP3A4 inhibitors if concomitant medications that are metabolized by CYP3A4 are used. No dietary restrictions required solely for NIKTIMVO.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Limited data. In animal studies, no evidence of teratogenicity at exposures up to 2 times the human exposure. However, potential for fetal harm due to immune modulation. Risk cannot be excluded. Use only if benefit outweighs risk. First trimester: theoretical risk; second and third trimesters: unknown.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Unknown if excreted in human milk. No M/P ratio available. Due to potential for adverse reactions in breastfed infants, advise against breastfeeding during treatment and for at least 5 half-lives after last dose.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No specific dose adjustments recommended due to lack of pharmacokinetic data in pregnancy. However, physiological changes in pregnancy may alter exposure; monitor for efficacy and toxicity.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
NIKTIMVO (nivolumab) is an immune checkpoint inhibitor targeting PD-1. Monitor for immune-related adverse events (ir AEs), especially pneumonitis, colitis, hepatitis, and endocrinopathies. Infusion reactions may occur; premedicate with antihistamines and acetaminophen if indicated. Avoid use in patients with active autoimmune disease or those requiring chronic immunosuppression. Assess baseline liver, renal, and thyroid function before initiation.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Report any new or worsening symptoms such as cough, chest pain, shortness of breath, diarrhea, abdominal pain, jaundice, rash, or thyroid dysfunction signs (e.g., fatigue, weight changes).,Do not receive live vaccines during treatment and for at least 1 month after last dose.,Inform your doctor of all medications, including over-the-counter drugs, especially immunosuppressants or corticosteroids.,Use effective contraception during treatment and for at least 5 months after the last dose.,Notify your doctor immediately if you experience symptoms of infusion reactions (fever, chills, itching, dizziness).
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIKTIMVO vs AGRYLIN, answered by our medical review team.
NIKTIMVO is a Antineoplastic agent that works by NIKTIMVO is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, lowering blood glucose levels independently of insulin.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIKTIMVO and AGRYLIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIKTIMVO is: Nivolumab 240 mg intravenously over 30 minutes every 2 weeks, or 480 mg intravenously over 30 minutes every 4 weeks.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIKTIMVO and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIKTIMVO is classified as Category C. Limited data. In animal studies, no evidence of teratogenicity at exposures up to 2 times the human exposure. However, potential for fetal harm due to immune modulation. Risk canno. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.